Production (Stage)
scPharmaceuticals Inc.
SCPH
$3.55
-$0.03-0.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 92.59% | 99.31% | 164.12% | 391.70% | 195.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 92.59% | 99.31% | 164.12% | 391.70% | 195.78% |
| Cost of Revenue | 94.45% | 123.63% | 206.86% | 549.72% | 195.04% |
| Gross Profit | 91.82% | 89.34% | 147.15% | 348.13% | 196.09% |
| SG&A Expenses | 22.70% | 31.60% | 50.83% | 44.74% | 60.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.39% | 33.44% | 51.18% | 46.16% | 61.25% |
| Operating Income | -11.99% | -7.12% | -22.29% | -4.98% | -37.23% |
| Income Before Tax | -39.93% | -36.44% | -124.54% | -20.74% | -25.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.93% | -36.44% | -124.54% | -20.74% | -25.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.93% | -36.44% | -124.54% | -20.74% | -25.85% |
| EBIT | -11.99% | -7.12% | -22.29% | -4.98% | -37.23% |
| EBITDA | -12.01% | -7.13% | -22.30% | -4.99% | -37.25% |
| EPS Basic | -1.55% | 1.01% | -86.96% | -19.85% | -22.12% |
| Normalized Basic EPS | -3.09% | 14.73% | -93.85% | -19.86% | -22.18% |
| EPS Diluted | -1.55% | 1.01% | -86.96% | -19.85% | -22.12% |
| Normalized Diluted EPS | -3.09% | 14.73% | -93.85% | -19.86% | -22.18% |
| Average Basic Shares Outstanding | 37.80% | 37.84% | 20.12% | 0.75% | 3.05% |
| Average Diluted Shares Outstanding | 37.80% | 37.84% | 20.12% | 0.75% | 3.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |